SEC Form 4	
------------	--

## FORM 4

obligations may continue. See

Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APP	ROVAL
OMB Number:	3235-0287

0.5

	OMB Number: 3
	Estimated average burden
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

		., .,						
1. Name and Address of Reporting Ferson		2. Issuer Name and Ticker or Trading Symbol Shockwave Medical, Inc. [SWAV]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
PUCKETT DAN		bioekwave medical, me. [ 50m ]		Director	10% Owner			
			х	Officer (give title	Other (specify			
(Last) (First) (I	Middle)	3. Date of Earliest Transaction (Month/Day/Year)		below)	below)			
		07/01/2021		Chief Financia	l Officer			
C/O SHOCKWAVE MEDICAL, INC								
5403 BETSY ROSS DRIVE								
,		4. If Amendment, Date of Original Filed (Month/Day/Year)		ridual or Joint/Group Filir	ng (Check Applicable			
(Street)			Line)					
	95054		X	Form filed by One Rep	porting Person			
SANTA CLARA CA S	10004			Form filed by More tha Person	an One Reporting			
(City) (State) (A	Zip)							

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

		· · · ·									
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11150.4)	
Common Stock	07/01/2021		<b>M</b> <sup>(1)</sup>		342	A	\$3.42	46,130	D		
Common Stock	07/01/2021		<b>M</b> <sup>(1)</sup>		251	A	\$4.03	46,381	D		
Common Stock	07/01/2021		<b>M</b> <sup>(1)</sup>		1,907	A	\$17	48,288	D		
Common Stock	07/01/2021		<b>S</b> <sup>(1)</sup>		1,181	D	\$188.83(2)	47,107	D		
Common Stock	07/01/2021		<b>S</b> <sup>(1)</sup>		918	D	\$189.89(3)	46,189	D		
Common Stock	07/01/2021		<b>S</b> <sup>(1)</sup>		201	D	\$190.47(4)	45,988	D		
Common Stock	07/01/2021		<b>S</b> <sup>(1)</sup>		200	D	\$191.36(5)	45,788	D		

 
 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) Securities (Month/Day/Year)			of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares								
Employee Stock Option (Right to Buy)	\$3.42	07/01/2021		<b>M</b> <sup>(1)</sup>			341	(6)	08/03/2027	Common Stock	341	\$0	0	D					
Employee Stock Option (Right to Buy)	\$4.03	07/01/2021		M <sup>(1)</sup>			251	(7)	07/19/2028	Common Stock	251	\$0	3,605	D					
Employee Stock Option (Right to Buy)	\$17	07/01/2021		<b>M</b> <sup>(1)</sup>			1,908	(8)	03/06/2029	Common Stock	1,908	\$0	29,757	D					

## Explanation of Responses:

1. All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 8/8/2019.

2. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$188.26 to \$189.23. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

3. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$189.29 to \$190.15. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

4. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$190.30 to \$190.63. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

5. The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from \$191.34 to \$191.37. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

6. 1/48th of the shares subject to the option shall vest monthly from 07/21/2017.

7. 1/48th of the shares subject to the option shall vest monthly from 07/19/2018.

 $8. \ 1/48 th$  of the shares subject to the option shall vest monthly from 03/06/2019.

<u>/s/ Wade Estey, as attorney-in-</u><u>07/02/2021</u> fact for Dan Puckett

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.